SEARCH
Search Details
OBATA DaisukeUniversity Hospital / Center for Clinical ResearchAssociate Professor
Research activity information
■ Paper- INTRODUCTION: Clinical Evaluation Reports (CERs) have been an accepted pathway for medical device regulatory approval in Japan, yet their utilization and the characteristics of literature included in CERs remain poorly understood. This study aimed to describe CER utilization patterns and identify characteristics to inform manufacturers and regulators about acceptable CER-based regulatory applications. METHODS: We analyzed 898 medical devices approved in Japan between FY2009 and FY2021 using clinical evidence based on PMDA public data. We compared characteristics between devices approved based on CERs and those approved based on clinical trial data among formally deliberated new devices (CER: n = 18; clinical trial: n = 125). For the 18 CER-based devices, we further analyzed cited literature characteristics. RESULTS: Of the 898 devices, 257 (28.6%) were approved based on CERs, with the proportion exceeding 20% annually since FY2011. Among formally deliberated new devices, CER-based approvals were significantly more likely to be designated as high medical need devices (55.6% vs. 24.0%; p = 0.010), while regulatory review periods were comparable between groups (median 12.1 vs. 12.3 months). In the literature analysis, 7 of 18 CERs included no articles reporting clinical studies conducted in Japan, 3 lacked high-level evidence literature (systematic reviews, meta-analyses, or RCTs), and 6 utilized literature on prior-generation or similar devices. CONCLUSIONS: CER-based approvals have increased steadily since FY2009. The literature cited showed diversity in source and level of evidence, suggesting that PMDA evaluates submissions based on device characteristics. These findings provide a descriptive reference for manufacturers planning CER-based submissions and regulators in Japan.Jun. 2026, Therapeutic innovation & regulatory science, English, International magazineScientific journal
- BACKGROUND: In Japan, to promote the development and application of unapproved and off-label drugs, a review pathway known as the "public knowledge-based application" was established in 1999. This pathway allows companies to submit applications without clinical trials if the drug has publicly known efficacy and safety and is deemed highly necessary for medical purposes. OBJECTIVE: The aim of this study is to analyze information published on government websites and to clarify what the criteria for "public knowledge" or "medically necessary" that apply to "public knowledge-based application" that are not yet clear. METHODS: We analyzed the correlation between the evidence presented in applications and the progression from the determination of high medical needs to regulatory approval for unapproved and off-label drugs requested for development by patient groups and academic societies in Japan between August 2013 and March 2022. RESULTS: Of the 171 requests, 54 were judged to meet the criteria for medical necessity, and 25 of these were judged to meet the criteria for public knowledge-based application. Of the requests that did not meet the criteria for medical necessity, 90% involved existing domestic therapies. Seventy-two percent of requests meeting the public knowledge-based application criteria involved drugs with standard use in 6 Western countries. CONCLUSION: This study suggests that the availability of existing domestic therapies and the approval or standard use status of a drug in the 6 Western countries influence the judgment of the applicability of public knowledge-based applications.Jun. 2026, Current therapeutic research, clinical and experimental, 104, 100819 - 100819, English, International magazineScientific journal
- Springer Science and Business Media LLC, Feb. 2025, Scientific Reports, 15(1) (1)Scientific journal
- Dec. 2024, Nature Communications, 15(1) (1)Scientific journal
- Springer Science and Business Media LLC, Sep. 2024, Communications Biology, 7(1) (1)[Refereed]Scientific journal
- 日本分子腫瘍マーカー研究会, Feb. 2024, 日本分子腫瘍マーカー研究会誌, 39, 8 - 9, Japanese
- Abstract Background We have previously reported apolipoprotein A2-isoforms (apoA2-is) as candidate plasma biomarkers for early-stage pancreatic cancer. The aim of this study was the clinical development of apoA2-is. Methods We established a new enzyme-linked immunosorbent sandwich assay for apoA2-is under the Japanese medical device Quality Management System requirements and performed in vitro diagnostic tests with prespecified end points using 2732 plasma samples. The clinical equivalence and significance of apoA2-is were compared with CA19-9. Results The point estimate of the area under the curve to distinguish between pancreatic cancer (n = 106) and healthy controls (n = 106) was higher for apoA2-ATQ/AT [0.879, 95% confidence interval (CI): 0.832–0.925] than for CA19-9 (0.849, 95% CI 0.793–0.905) and achieved the primary end point. The cutoff apoA2-ATQ/AT of 59.5 μg/mL was defined based on a specificity of 95% in 2000 healthy samples, and the reliability of specificities was confirmed in two independent healthy cohorts as 95.3% (n = 106, 95% CI 89.4–98.0%) and 95.8% (n = 400, 95% CI 93.3–97.3%). The sensitivities of apoA2-ATQ/AT for detecting both stage I (47.4%) and I/II (50%) pancreatic cancers were higher than those of CA19-9 (36.8% and 46.7%, respectively). The combination of apoA2-ATQ/AT (cutoff, 59.5 μg/mL) and CA19-9 (37 U/mL) increased the sensitivity for pancreatic cancer to 87.7% compared with 69.8% for CA19-9 alone. The clinical performance of apoA2-is was blindly confirmed by the National Cancer Institute Early Detection Research Network. Conclusions The clinical performance of ApoA2-ATQ/AT as a blood biomarker is equivalent to or better than that of CA19-9.Springer Science and Business Media LLC, Jan. 2024, Journal of GastroenterologyScientific journal
- Dec. 2023, Nature Genetics, 55(12) (12), 2065 - 2074[Refereed]Scientific journal
- Dec. 2023, Nature Communications, 14(1) (1)Scientific journal
- Dec. 2023, Nature Communications, 14(1) (1)Scientific journal
- (一財)日本消化器病学会, Oct. 2023, 日本消化器病学会雑誌, 120(臨増大会) (臨増大会), A750 - A750, Japanese
- (一財)日本消化器病学会, Oct. 2023, 日本消化器病学会雑誌, 120(臨増大会) (臨増大会), A754 - A754, Japanese
- 日本分子腫瘍マーカー研究会, Sep. 2023, 日本分子腫瘍マーカー研究会プログラム・講演抄録, 43回, 52 - 53, JapaneseApolipoprotein-A2 isoformを利用した膵がん血液バイオマーカーの臨床開発
- Jul. 2023, Cell Reports Medicine, 4(7) (7)Scientific journal
- Objective We assessed the factors associated with overlap between functional dyspepsia (FD) and nonerosive reflux disease (NERD) in endoscopy-based Helicobacter pylori-uninfected Japanese health checkup participants. Methods We utilized baseline data from 3,085 individuals who underwent upper endoscopy for health screening in a prospective, multicenter cohort study. The participants were asked to complete a questionnaire detailing their upper abdominal symptoms and lifestyle. Anxiety was assessed using the State-Trait Anxiety Inventory (STAI) score. FD, postprandial distress syndrome (PDS), and epigastric pain syndrome (EPS) were defined according to the Rome III criteria. NERD was defined as heartburn or regurgitation ≥1 day/week without erosive esophagitis. Results Of the 3,085 participants, 73 (2.4%), 97 (3.1%), and 84 (2.7%) had FD alone, NERD alone, and FD-NERD overlap, respectively. Factors associated with FD-NERD-overlap participants compared with participants with neither FD nor NERD were women [odds ratio (OR): 2.08, 95% confidence interval (CI) 1.24-3.52], body mass index (BMI) <18.5 (OR: 2.87, 95% CI: 1.56-5.07), alcohol consumption ≥20 g/day (OR: 1.85, 95% CI: 1.06-3.15), and a high STAI score (OR: 2.53, 95% CI: 1.62-4.00). Increasing age (OR: 1.06, 95% CI: 1.01-1.11) and EPS symptoms [pure EPS (OR: 3.67, 95% CI: 1.65-8.51) and PDS-EPS overlap (OR: 11.6, 95% CI: 4.09-37.2)] were associated with FD-NERD overlap vs. FD alone. Women (OR: 3.17, 95% CI: 1.47-7.04), BMI <18.5 (OR: 3.03, 95% CI: 1.04-9.90), and acid reflux symptoms ≥2 days a week (OR: 3.57, 95% CI: 1.83-7.14) were associated with FD-NERD overlap vs. NERD alone. Conclusion Understanding the clinical features of overlap between FD and NERD will lead to better management.Jul. 2023, Internal medicine (Tokyo, Japan), English, Domestic magazineScientific journal
- INTRODUCTION: Favorable long-term outcomes of endoscopic submucosal dissection (ESD) for early remnant gastric cancer (ERGC) have been reported in single-center studies from advanced institutions. However, no studies have examined the long-term outcomes using a multicenter database. This study aimed to investigate the long-term outcomes of the aforementioned approach using a large multicenter database. METHODS: This retrospective multicenter cohort study included 242 cases with 256 lesions that underwent ESD for ERGC between April 2009 and March 2019 across 12 centers. We investigated the long-term outcomes of these patients with the Kaplan-Meier method, and the relationship between curability, additional treatment, or hospital category, and the survival time was evaluated using the log-rank test. RESULTS: During the median follow-up period of 48.4 months, the 5-year overall survival rate was 81.3%, and the 5-year gastric cancer-specific survival rate was 98.1%. The survival time of patients of endoscopic curability (eCura) C-2 without additional surgery was significantly shorter than the corresponding of patients of eCura A/B/C-1 and eCura C-2 with additional surgery. There was no significant difference in either overall survival or gastric cancer-specific survival rate between the high-volume and non-high-volume hospitals. CONCLUSION: The gastric cancer-specific survival of ESD for ERGC using a multicenter database was favorable. ESD for ERGC is widely applicable regardless of the hospital case volume. Management in accordance with the latest guidelines will lead to long-term survival.Jun. 2023, Digestion, 1 - 10, English, International magazineScientific journal
- Abstract Background Type 2 diabetes is a common disease around the world and its major complications are diabetic retinopathy (DR) and diabetic kidney disease (DKD). Persons with type 2 diabetes with complications, especially who have both DR and DKD, have poorer prognoses than those without complications. Therefore, prevention and early identification of the complications of type 2 diabetes are necessary to improve the prognosis of persons with type 2 diabetes. The aim of this study is to identify factors associated with the development of multiple complications of type 2 diabetes. Methods We profiled serum metabolites of persons with type 2 diabetes with both DR and DKD (N = 141) and without complications (N = 159) using a comprehensive non-targeted metabolomics approach with mass spectrometry. Based on the serum metabolite profiles, case–control comparisons and metabolite set enrichment analysis (MSEA) were performed. Results Here we show that five metabolites (cyclohexylamine, P = 4.5 × 10−6; 1,2-distearoyl-glycero-3-phosphocholine, P = 7.3 × 10−6; piperidine, P = 4.8 × 10−4; N-acetylneuraminic acid, P = 5.1 × 10−4; stearoyl ethanolamide, P = 6.8 × 10−4) are significantly increased in those with the complications. MSEA identifies fatty acid biosynthesis as the type 2 diabetes complications-associated biological pathway (P = 0.0020). Conclusions Our metabolome analysis identifies the serum metabolite features of the persons with type 2 diabetes with multiple complications, which could potentially be used as biomarkers.Springer Science and Business Media LLC, Jan. 2023, Communications Medicine, 3(1) (1), 5 - 5, English, International magazineScientific journal
- Jun. 2022, Nature Genetics, 54(6) (6), 792 - 803Scientific journal
- Apr. 2022, Nature Genetics, 54(4) (4), 450 - 458Scientific journal
- Mar. 2022, Journal of Human Genetics, 67(3) (3), 149 - 156Scientific journal
- 日本分子腫瘍マーカー研究会, 2022, 日本分子腫瘍マーカー研究会誌, 37, 49 - 50, Japaneseリアルワールドエビデンスを支援する「バイオマーカー迅速検証プラットフォーム」について
- Dec. 2021, Nature Communications, 12(1) (1)Scientific journal
- Current genome-wide association studies do not yet capture sufficient diversity in populations and scope of phenotypes. To expand an atlas of genetic associations in non-European populations, we conducted 220 deep-phenotype genome-wide association studies (diseases, biomarkers and medication usage) in BioBank Japan (n = 179,000), by incorporating past medical history and text-mining of electronic medical records. Meta-analyses with the UK Biobank and FinnGen (ntotal = 628,000) identified ~5,000 new loci, which improved the resolution of the genomic map of human traits. This atlas elucidated the landscape of pleiotropy as represented by the major histocompatibility complex locus, where we conducted HLA fine-mapping. Finally, we performed statistical decomposition of matrices of phenome-wide summary statistics, and identified latent genetic components, which pinpointed responsible variants and biological mechanisms underlying current disease classifications across populations. The decomposed components enabled genetically informed subtyping of similar diseases (for example, allergic diseases). Our study suggests a potential avenue for hypothesis-free re-investigation of human diseases through genetics.Oct. 2021, Nature genetics, 53(10) (10), 1415 - 1424, English, International magazineScientific journal
- Jun. 2021, Nature Medicine, 27(6) (6), 1012 - 1024Scientific journal
- BACKGROUND: Endoscopic submucosal dissection (ESD) for remnant gastric cancer (RGC) after distal gastrectomy (DG) is considered technically challenging due to the narrow working space, and severe fibrosis and staples from the previous surgery. Technical difficulties of ESD for RGC after DG have not been thoroughly investigated. This study aimed to develop and validate a risk-scoring system for assessing the technical difficulty of ESD for RGC after DG in a large multicenter cohort. METHODS: We investigated patients who underwent ESD for RGC after DG in 10 institutions between April 2008 and March 2018. A difficult case was defined as ESD lasting ≥ 120 min, involving piecemeal resection, or the occurrence of perforation during the procedure. A risk-scoring system for the technical difficulty of the procedure was developed based on multiple logistic regression analyses, and its performance was internally validated using bootstrapping. RESULTS: A total of 197 consecutive patients with 201 lesions were analyzed. There were 90 and 111 difficult and non-difficult cases, respectively. The scoring model consisted of four independent risk factors and points of risk scores were assigned for each as follows: tumor size > 20 mm: 2 points; anastomosis site: 2 points; suture line: 1 point; and non-expert endoscopist: 2 points. The C-statistics of the scoring system for technical difficulty was 0.72. CONCLUSIONS: We developed a validated risk-scoring model for predicting the technical difficulty of ESD for RGC after DG that can contribute to its safer and more reliable performance.Apr. 2021, Surgical endoscopy, 36(2) (2), 1482 - 1489, English, International magazineScientific journal
- Apr. 2020, JGH open : an open access journal of gastroenterology and hepatology, 4(2) (2), 251 - 255, English, International magazine[Refereed]Scientific journal
- Mar. 2020, BMJ case reports, 13(3) (3), English, International magazine[Refereed]Scientific journal
- Aug. 2018, Surgical endoscopy, 32(8) (8), 3622 - 3629, English, International magazine[Refereed]Scientific journal
- 2017, Digestion, 96(1) (1), 52 - 59, English, International magazine[Refereed]Scientific journal
- 2016, Gastroenterological Endoscopy, 58(7) (7), 1215 - 1220A case of eosinophilic gastroenteritis with difficulty in its diagnosis[Refereed]Scientific journal
- Apr. 2014, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 17(2) (2), 371 - 6, English, Domestic magazine[Refereed]Scientific journal
- Nov. 2013, Surgical endoscopy, 27(11) (11), 4241 - 9, English, International magazine[Refereed]Scientific journal
- Dec. 2012, Surgical laparoscopy, endoscopy & percutaneous techniques, 22(6) (6), 546 - 7, English, International magazine
- Mar. 2012, World journal of gastroenterology, 18(12) (12), 1295 - 307, English, International magazine[Refereed]Scientific journal
- Mar. 2012, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 24(2) (2), 100 - 9, English, International magazine[Refereed]Scientific journal
- Feb. 2011, The Kobe journal of medical sciences, 56(5) (5), E204-13, English, Domestic magazineSurveillance after colorectal polypectomy; comparison between Japan and U.S.[Refereed]Scientific journal
- Jun. 2010, Journal of gastroenterology, 45(6) (6), 600 - 7, English, Domestic magazine[Refereed]Scientific journal
- 2010, Progress in Biomedical Optics and Imaging - Proceedings of SPIE, 7562[Refereed]International conference proceedings
- 2010, Endoscopy, 42(SUPPL. 2) (SUPPL. 2)[Refereed]Scientific journal
- Nov. 2007, International journal of colorectal disease, 22(11) (11), 1409 - 1409, English, International magazine
- Mar. 2006, Journal of gastroenterology, 41(3) (3), 282 - 3, English, Domestic magazine
- (一財)日本消化器病学会, Jul. 2022, 日本消化器病学会雑誌, 119(7) (7), 589 - 599, Japanese
- 2022, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 119(7) (7), 589 - 599, Japanese, Domestic magazine
- 日本分子腫瘍マーカー研究会, 2022, 日本分子腫瘍マーカー研究会誌, 37, 49 - 50, Japanese
- 日本分子腫瘍マーカー研究会, Sep. 2021, 日本分子腫瘍マーカー研究会プログラム・講演抄録, 41回, 86 - 87, Japaneseリアルワールドエビデンスを支援する「バイオマーカー迅速検証プラットフォーム」について
- (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1343 - 1343, Japanese内視鏡的診断が困難であった腸管内腔側に内翻した虫垂子宮内膜症の一例
- (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1351 - 1351, Japanese門脈内ガスを伴った気腫性胃炎の一例
- (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1343 - 1343, Japanese内視鏡的診断が困難であった腸管内腔側に内翻した虫垂子宮内膜症の一例
- (一社)日本消化器内視鏡学会, Aug. 2020, Gastroenterological Endoscopy, 62(Suppl.1) (Suppl.1), 1351 - 1351, Japanese門脈内ガスを伴った気腫性胃炎の一例
- (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A277 - A277, Japanese
- (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A315 - A315, Japanese
- (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A277 - A277, Japanese
- (一財)日本消化器病学会, Jul. 2020, 日本消化器病学会雑誌, 117(臨増総会) (臨増総会), A315 - A315, Japanese
- 2020, 日本消化器病学会雑誌(Web), 117イマチニブの使用により人工肛門増設を免れた直腸GISTの一例
- (一社)日本消化器内視鏡学会, May 2019, Gastroenterological Endoscopy, 61(Suppl.1) (Suppl.1), 887 - 887, Japaneseナツメ種子の誤飲による小腸穿通・腹腔内膿瘍に対して、内視鏡的な除去による保存的加療にて治癒した一例
- (一社)日本消化器内視鏡学会, May 2019, Gastroenterological Endoscopy, 61(Suppl.1) (Suppl.1), 975 - 975, Japanese上行結腸に認めた稀な形態を呈した良性リンパ濾胞性ポリープの一例
- (一財)日本消化器病学会, Mar. 2019, 日本消化器病学会雑誌, 116(臨増総会) (臨増総会), A425 - A425, Japanese一般病院における高齢者への便秘症診療の現状と治療検討
- (一社)日本消化器内視鏡学会, Oct. 2018, Gastroenterological Endoscopy, 60(Suppl.2) (Suppl.2), 2066 - 2066, Japanese胃ESDにおける水平断端陽性症例に対する治療戦略
- (一財)日本消化器病学会, Oct. 2018, 日本消化器病学会雑誌, 115(臨増大会) (臨増大会), A695 - A695, Japanese当院における胃ESD後出血リスク因子についての検討
- 日本膵臓学会, May 2018, 膵臓, 33(3) (3), 319 - 319, Japanese急性膵炎重症度判定基準をめぐる諸問題 重症急性膵炎患者におけるWON発生因子の検討
- 日本膵臓学会, May 2018, 膵臓, 33(3) (3), 590 - 590, Japanese急性膵炎後被包化膵壊死に対しネクロセクトミー施行中に出血を合併し死亡した2剖検例
- (一社)日本消化管学会, Feb. 2018, 日本消化管学会雑誌, 2(Suppl.) (Suppl.), 111 - 111, Japanese胃癌の低侵襲治療の現状と将来 早期胃癌ESD後7日目の胃内残渣物量評価による間接的胃排出障害関連因子についての検討
- 2018, 日本消化器病学会雑誌(Web), 115当院における胃ESD後出血リスク因子についての検討
- 2018, 日本消化管学会雑誌, 2(Supplement) (Supplement)早期胃癌ESD後7日目の胃内残渣物量評価による間接的胃排出障害関連因子についての検討
- 2018, Gastroenterological Endoscopy (Web), 60(Supplement2) (Supplement2)胃ESDにおける水平断端陽性症例に対する治療戦略
- (一財)日本消化器病学会, Sep. 2017, 日本消化器病学会雑誌, 114(臨増大会) (臨増大会), A749 - A749, JapaneseDIC合併重症急性膵炎へのThrombomodulin α投与に対するPerfusion CTの検討
- (一財)日本消化器病学会, Sep. 2017, 日本消化器病学会雑誌, 114(臨増大会) (臨増大会), A833 - A833, Japanese終末期癌患者の腹水へのtriamcinolone acetonide腹腔内投与及びKM-CARTの臨床的検討
- (一社)日本消化器内視鏡学会, Sep. 2017, Gastroenterological Endoscopy, 59(Suppl.2) (Suppl.2), 2222 - 2222, Japaneseびらん性食道炎におけるボノプラザンとエソメプラゾールの症状改善効果の比較
- (一社)日本消化器内視鏡学会, Sep. 2017, Gastroenterological Endoscopy, 59(Suppl.2) (Suppl.2), 2232 - 2232, Japanese胃ESD後の残渣量評価による胃運動機能障害の検討
- 日本胆道学会, Aug. 2017, 胆道, 31(3) (3), 485 - 485, Japanese後期高齢者におけるDIC合併胆道感染時のThrombomodulin αの投与効果
- (一財)日本消化器病学会, Mar. 2017, 日本消化器病学会雑誌, 114(臨増総会) (臨増総会), A288 - A288, Japanese胃ESD後潰瘍におけるプロトンポンプ阻害剤とボノプラザンの術後合併症と潰瘍治癒過程の比較検討
- 2017, Gastroenterological Endoscopy (Web), 59(Supplement2) (Supplement2)びらん性食道炎におけるボノプラザンとエソメプラゾールの症状改善効果の比較
- 2017, Gastroenterological Endoscopy (Web), 59(Supplement2) (Supplement2)胃ESD後の残渣量評価による胃運動機能障害の検討
- (一社)日本消化器内視鏡学会, Jul. 2016, Gastroenterological Endoscopy, 58(7) (7), 1215 - 1220, Japanese診断に苦慮した好酸球性胃腸炎の1例
- 2016, Gastroenterological Endoscopy (Web), 58(7) (7)診断に苦慮した好酸球性胃腸炎の1例
- (株)先端医学社, Aug. 2015, G.I.Research, 23(4) (4), 282 - 287, Japanese【消化器癌におけるレーザー光を用いた診断・治療】炭酸ガスレーザーによる内視鏡的粘膜下層剥離術
- (一社)日本消化器内視鏡学会, Apr. 2014, Gastroenterological Endoscopy, 56(Suppl.1) (Suppl.1), 1385 - 1385, Japanese過度の画像強調はHp内視鏡診断の妨げになる
- 【H.pylori除菌後長期経過による内視鏡像の変化】H.pylori除菌後10年以上観察例におけるH.pylori胃炎除菌後内視鏡像の検討および除菌直後と10年以上経過時点でのNBI拡大像の比較H.pylori(HP)除菌後の短期(3ヵ月)と長期観察例(10年以上)との内視鏡像の違いを検討した。56例の除菌施行前の内視鏡検査から、最終内視鏡までの平均期間は12.3年であった。びまん性発赤(DE)、発赤小陥凹(Dep)、滲出液(EX)、集合細静脈(RAC)の除菌直後の変化は長期経過後もほぼ不変であった。ヒダ肥厚(EF)は縮小傾向であったが長期経過中にも完全には正常化しなかった。点状発赤(SE)は完全消失がある一方、残存例もあった。通常の白色光内視鏡ではとらえられない除菌前後の変化がNBI拡大観察でとらえられるか検討した。除菌後3ヵ月目でみられた変化(改善)は、除菌後10年以上経過した症例でもほぼ同様に認められた。すなわち除菌後短期と長期経過例とのあいだで顕著な違いは認めなかった。(有)科学評論社, Aug. 2013, 消化器内科, 57(2) (2), 111 - 118, Japanese
- (株)東京医学社, Aug. 2013, 消化器内視鏡, 25(8) (8), 1107 - 1113, Japanese【治療に直結する大腸腫瘍診断のストラテジー】大腸内視鏡検査における病変の拾い上げと見逃し
- (株)先端医学社, Jun. 2013, Helicobacter Research, 17(3) (3), 240 - 244, Japanese【慢性胃炎へのHelicobacter pylori除菌療法 保険適用拡大】保険適用拡大を受けて現場からの意見 内視鏡所見を重視して落とし穴を回避する
- (株)東京医学社, Mar. 2013, 消化器内視鏡, 25(3) (3), 433 - 443, Japanese【必修!大腸ESD】病変のサイズと部位に応じた基本的治療戦略
- (株)医学書院, Feb. 2013, 胃と腸, 48(2) (2), 145 - 154, Japanese【大腸ESDの適応と実際】深達度からみた大腸ESDの実際と限界
- (一社)日本医療情報学会, Nov. 2012, 医療情報学連合大会論文集, 32回, 446 - 449, Japanese内視鏡検査進捗管理システムの構築による部門システム機能の拡張
- (NPO)日本レーザー医学会, Oct. 2012, 日本レーザー医学会誌, 33(3) (3), 278 - 278, Japanese消化器科におけるレーザーの現状と新展開 CO2レーザーによる新しい消化器内視鏡治療技術の開発
- (一社)日本消化器内視鏡学会, Apr. 2012, Gastroenterological Endoscopy, 54(Suppl.1) (Suppl.1), 959 - 959, Japanese内視鏡関連機器の開発と今後の展望 光吸収材とCO2レーザーによる新たなESD技術の開発
- 05 Mar. 2012, 電気学会研究会資料. OQD, 光・量子デバイス研究会, 2012(19) (19), 1 - 5, JapaneseDevelopment of endoscopic submucosal dissection for digestive organ cancer using carbon dioxide laser
- (公社)日本超音波医学会, Mar. 2012, 超音波医学, 39(2) (2), 199 - 199, Japanese腹部超音波検査にて上腸間膜症候群を疑った十二指腸狭窄症の1例
- (NPO)日本レーザー医学会, Feb. 2012, 日本レーザー医学会誌, 32(4) (4), 521 - 521, JapaneseCO2レーザーを用いた安全な内視鏡的粘膜下層剥離術の開発
- 医歯薬出版(株), Feb. 2012, 医学のあゆみ, 240(6) (6), 523 - 526, Japanese【レーザー医工学の進歩】炭酸ガスレーザーを用いた内視鏡的粘膜下層剥離術
- 2012, Endoscopy, 44(SUPPL. 2) (SUPPL. 2)Book review
- The Japan Society of Mechanical Engineers, 2012, The Proceedings of the Bioengineering Conference Annual Meeting of BED/JSME, 2012(0) (0), _7E13 - 1_-_7E13-2_, Japanese
- (株)医学書院, Sep. 2011, 胃と腸, 46(10) (10), 1511 - 1519, Japanese【大腸SM癌に対する内視鏡治療の適応拡大】主題 内視鏡治療手技における注意点 SM浸潤の可能性がある大腸癌に対するESD
- (一社)日本消化器内視鏡学会, Sep. 2011, Gastroenterological Endoscopy, 53(Suppl.2) (Suppl.2), 2487 - 2487, Japanese内視鏡手術の新展開 光吸収剤とCO2レーザーによる新たなESD技術の開発
- (株)新興医学出版社, Jul. 2011, Modern Physician, 31(臨時増刊号) (臨時増刊号), 33 - 39, Japanese【上部消化管腫瘍内視鏡診断学の新時代】早期胃癌診断の新時代 早期胃癌の肉眼分類 ESD適用有無に向けて診断学は変わるか?
- (一社)日本消化器内視鏡学会, Mar. 2011, Gastroenterological Endoscopy, 53(Suppl.1) (Suppl.1), 675 - 675, Japanese内視鏡関連機器の進歩と課題 光吸収剤とCO2レーザーによる新たなESD技術の開発
- Endoscopic submucosal dissection (ESD) has attracted a great deal of attention as a new treatment forThe Laser Society of Japan, 15 Feb. 2011, The Review of Laser Engineering, 39(2) (2), 111 - 117, Japanese
- (NPO)日本レーザー医学会, Jan. 2011, 日本レーザー医学会誌, 31(4) (4), 463 - 463, JapaneseCO2レーザーを用いた食道がんの内視鏡的粘膜下層剥離術の検討
- (NPO)日本レーザー医学会, Oct. 2010, 日本レーザー医学会誌, 31(3) (3), 335 - 335, Japanese炭酸ガスレーザーと光吸収材を用いた内視鏡的粘膜下層剥離術の開発
- 03 Sep. 2010, レーザー学会研究会報告 = Reports on the Topical meeting of the Laser Society of Japan, 402, 37 - 42, JapaneseEndoscopic Submucosal Dissection for Gastric Cancer using Carbon Dioxide Laser
- (一社)日本消化器内視鏡学会, Sep. 2010, Gastroenterological Endoscopy, 52(Suppl.2) (Suppl.2), 2538 - 2538, Japanese十二指腸乳頭括約筋機能不全(SOD)に対しEST後再燃した一例
- (株)東京医学社, Sep. 2010, 消化器内視鏡, 22(9) (9), 1532 - 1537, Japanese【救命・救急と内視鏡】誤飲・誤嚥 消化管異物に対する内視鏡の役割 緊急性のある場合とない場合、小児例、小腸異物など
- (一社)日本消化器内視鏡学会, Apr. 2010, Gastroenterological Endoscopy, 52(Suppl.1) (Suppl.1), 810 - 810, Japanese食道・胃腫瘍に対するImage-enhanced endoscopy(IEE)の臨床的意義 食道表在癌の深達度診断におけるNBI併用拡大内視鏡観察
- (NPO)日本レーザー医学会, Jan. 2010, 日本レーザー医学会誌, 30(4) (4), 471 - 471, Japanese炭酸ガスレーザーと光吸収剤を用いた選択的粘膜下層剥離
- (株)日本メディカルセンター, Nov. 2009, 臨床消化器内科, 24(13) (13), 1745 - 1749, Japanese内視鏡の読み方 ESD術前の側方範囲診断にNBI拡大観察および酢酸・インジゴカルミンサンドイッチ法が有用であった表層拡大型胃高分化腺癌の1例
- (株)日本メディカルセンター, Oct. 2009, 臨床消化器内科, 24(12) (12), 1633 - 1637, Japanese内視鏡の読み方 粘膜下腫瘍様の形態を呈した手術既往のないgastritis cystica profundaの1例
- (株)ヴァンメディカル, Aug. 2009, 消化器の臨床, 12(4) (4), 360 - 363, Japanese【消化器診療 示唆に富む症例】胃粘膜下腫瘍様の形態を呈した1例
- (NPO)日本医工学治療学会, Apr. 2009, 医工学治療, 21(Suppl.) (Suppl.), 99 - 99, Japanese炭酸ガスレーザーを用いた選択的粘膜下層剥離に関する基礎的検討
- (一社)日本消化器内視鏡学会, Apr. 2009, Gastroenterological Endoscopy, 51(Suppl.1) (Suppl.1), 953 - 953, Japanese上部消化管再建術後症例に対するERCP手技の成績について
- (一社)日本消化器内視鏡学会, Sep. 2008, Gastroenterological Endoscopy, 50(Suppl.2) (Suppl.2), 2254 - 2254, Japanese当院における食道表在癌の内視鏡的治療について
- (一社)日本消化器内視鏡学会, Sep. 2008, Gastroenterological Endoscopy, 50(Suppl.2) (Suppl.2), 2265 - 2265, JapaneseMR内視鏡システムによる新たな内視鏡的治療支援技術の開発
- (一社)日本消化器内視鏡学会, Sep. 2008, Gastroenterological Endoscopy, 50(Suppl.2) (Suppl.2), 2266 - 2266, Japanese早期胃癌に対する側方進展範囲診断の検討
- 日本胆道学会, Aug. 2008, 胆道, 22(3) (3), 398 - 398, Japanese上部消化管再建術後症例に対するERCP手技の成績について
- 日本胆道学会, Aug. 2008, 胆道, 22(3) (3), 399 - 399, Japanese胆管深部挿管困難例に対する膵管ステント併用プレカットの有用性、安全性に関する検討
- (株)東京医学社, Jun. 2008, 消化器内視鏡, 20(6) (6), 815 - 819, Japanese【当直医のための消化器救急診療マニュアル】上部消化管疾患が疑われる場合の検査・治療の進め方 消化管異物が疑われる場合の対応
- (有)科学評論社, May 2008, 臨床免疫・アレルギー科, 49(5) (5), 599 - 605, Japanese腸内細菌防御とFcγレセプター
- (一社)日本消化器内視鏡学会, Apr. 2008, Gastroenterological Endoscopy, 50(Suppl.1) (Suppl.1), 665 - 665, Japanese早期胃癌適応拡大病変に対するESDの現状と問題点 神戸大学附属病院および岸和田徳州会病院における早期胃癌適応拡大病変に対するESDの治療成績
- (一社)日本消化器内視鏡学会, Apr. 2008, Gastroenterological Endoscopy, 50(Suppl.1) (Suppl.1), 919 - 919, Japanese当院で経験した中・下咽頭微小癌の検討
- (一社)日本消化器内視鏡学会, Apr. 2008, Gastroenterological Endoscopy, 50(Suppl.1) (Suppl.1), 926 - 926, Japanese食道癌内視鏡治療後の術後狭窄予防に関する検討
- (一社)日本糖尿病学会, Jun. 2007, 糖尿病, 50(6) (6), 427 - 427, Japanese末端肥大症を伴った糖尿病治療にメトホルミンが奏功した1例
- (一社)日本消化器内視鏡学会, Apr. 2007, Gastroenterological Endoscopy, 49(Suppl.1) (Suppl.1), 868 - 868, Japanese大腸LSTに対する内視鏡切除についての考察
- (一社)日本消化器内視鏡学会, Apr. 2007, Gastroenterological Endoscopy, 49(Suppl.1) (Suppl.1), 906 - 906, Japanese当院における大腸憩室出血の検討
- (一社)日本消化器内視鏡学会, Apr. 2007, Gastroenterological Endoscopy, 49(Suppl.1) (Suppl.1), 960 - 960, Japanese出血性消化性潰瘍に対する内視鏡的止血術の検討
- (一財)日本消化器病学会, Mar. 2007, 日本消化器病学会雑誌, 104(臨増総会) (臨増総会), A118 - A118, Japanese高齢者総胆管結石に対する内視鏡治療の臨床的検討
- (株)日本メディカルセンター, Jul. 2006, 早期大腸癌, 10(4) (4), 365 - 365, Japanese術前診断に苦慮したII a+II c型大腸inflammatory fibroid polpyの1例
- (一社)日本糖尿病学会, Jun. 2006, 糖尿病, 49(6) (6), 491 - 491, Japanese中枢性尿崩症を合併2型糖尿病の1例
- (一財)日本消化器病学会, Mar. 2006, 日本消化器病学会雑誌, 103(臨増総会) (臨増総会), A263 - A263, Japanese当院における上部消化管異物症例の検討と食餌性異物(餅)による急性腹症の2例
- (一財)日本消化器病学会, Mar. 2006, 日本消化器病学会雑誌, 103(臨増総会) (臨増総会), A316 - A316, Japanese若年直腸癌患者に合併した膵リンパ上皮嚢胞の1例
- (一財)日本消化器病学会, Sep. 2005, 日本消化器病学会雑誌, 102(臨増大会) (臨増大会), A704 - A704, Japanese開院後1年6ケ月の期間に経験した食道表在癌の検討
- (一社)日本消化器内視鏡学会, Sep. 2005, Gastroenterological Endoscopy, 47(Suppl.2) (Suppl.2), 2040 - 2040, Japanese大腸LST(側方発育型大腸腫瘍)の治療方針
- (公社)日本超音波医学会, Jul. 2005, 超音波医学, 32(4) (4), 431 - 432, Japanese虫垂粘液嚢胞腺腫の1症例
- (一社)日本消化器内視鏡学会, Apr. 2005, Gastroenterological Endoscopy, 47(Suppl.1) (Suppl.1), 751 - 751, Japanese大腸拡大内視鏡診断におけるV型pit patternの検討
- (一社)日本消化器内視鏡学会, Apr. 2005, Gastroenterological Endoscopy, 47(Suppl.1) (Suppl.1), 758 - 758, Japanese上下部消化管出血に対するソフト凝固モードを用いた内視鏡的止血法に関する検討
- (一社)日本消化器内視鏡学会, Apr. 2005, Gastroenterological Endoscopy, 47(Suppl.1) (Suppl.1), 842 - 842, Japanese食餌性異物(餅)による急性腹症の2例
- (一社)日本糖尿病学会, Apr. 2005, 糖尿病, 48(4) (4), 270 - 270, Japanese冠動脈狭窄検出にcoronary CT angiographyが有用であった2症例
